Australian Biotechnology Company, Spinifex Pharmaceuticals has announced it has received an R&D Tax Incentive of approximately AUS$1.5 million. The Melbourne company established in June 2005 develops new medicinal drugs for the treatment and management of pain. The funds will be reinvested in further clinical development. Spinifex Pharmaceuticals CEO Tom McCarthy said: “This payment under the R&D tax incentive program is a good example of how Government initiatives can support innovative companies in the biotechnology industry and other sectors”. Click here […]
As the R&D Incentive deadline looms, companies are reminded that they need to register before 30 April to be eligible to claim for R&D activities for the 2012 financial year. This is the first year the benefits of the new R&D Tax Incentive will be seen. The R&D Tax Incentive (which replaced the R&D Tax Concession), provides generous support for companies who spent over $20,000 on experimental activities in FY2012. Companies with an aggregated turnover of less $20 million could […]
With the government’s recent R&D cuts from groups with revenue over $20 billion, there is some uncertainty surrounding the Australia’s commitment to research and development. A recent article in the Australian Financial Review explores the possibility that Australian businesses might look to invest elsewhere where R&D tax credits are more stable.
From 1 July 2012 companies can begin to claim under the new R&D Tax Incentive. The R&D Tax Application Form is now available on the AusIndustry website. The new legislation contains some significant changes, which any company intending to claim R&D for the 2011 tax year should be aware of. The new legislation provides the following incentives for companies: 45% refundable tax credit where turnover is below $20m (150% deduction) 40% non refundable tax credit where turnover is above $20m […]